The CCK-A receptor gene possibly associated with positive symptoms of schizophrenia SIR -The clinical heterogeneity of schizophrenia has long been recognized as the signs and symptoms of the disease are so complex and diverse. 1 To simplify the complexity of the clinical presentation of schizophrenia, a subdivision has been made into 'positive' and 'negative' symptoms.
2,3 The positive symptoms include hallucinations, delusions, disorganized speech, disorganized or catatonic behavior, and the negative symptoms include alogia, affective flattering and avolition. 4, 5 On the other hand, genetic factors may predispose an individual to schizophrenia although the mode of transmission remains unknown. Schizophrenia may be a genetically heterogeneous disease. The catecholamine pathway is widely thought to be abnormal in schizophrenia. Dopaminergic overactivity has been postulated for more than three decades. However, investigators have been unable to find a faulty gene amongst those coding for dopamine receptors and the enzymes responsible for dopamine metabolism. Cholecystokinin (CCK) has been found to coexist with dopamine in the same neurons and to act as a mediator in modulating dopaminergic activity. 7, 8 Since reduced CCK levels in the limbic lobe and reduced high affinity CCK binding in the hippocampus and frontal cortex have been observed in schizophrenia, 9,10 the genes coding for CCK receptors could be considered as candidate genes for schizophrenia. In a previous study, Wei and Hemmings reported that a Pst I polymorphic site in the boundary between intron 1 and exon 2 of the CCK-A receptor gene was significantly associated with auditory hallucinations in schizophrenia. 11 It is uncertain whether or not such an association really reflects linkage between the CCK-A receptor gene and psychotic symptoms in schizophrenia. It was thought important to replicate the work with a different ethnic population to rule out a false-positive result from ethnic differences in the frequency distribution of the DNA marker or from the population structure. The present work was therefore undertaken to examine the association between the CCK-A receptor gene and psychotic symptoms of schizophrenia in a Chinese population.
Eighty-four unrelated male schizophrenic individuals and 70 unrelated male healthy subjects were recruited in this study. They were all Han Chinese and came from the area of Beijing or nearby, Northern China. The patients fulfilled the ICD-10 criteria for chronic schizophrenia. Their mean duration of illness was 20.4 ± 10.2 years. All the subjects gave informed consent to participate in the genetic research. The detailed clinical pictures, medical histories and family history regarding mental illness were taken. The psychotic symptoms under study included auditory hallucinations, hallucination-delusion syndrome (HDS), Molecular Psychiatry bizarre delusion, paranoid delusions, emotional and social withdrawal and thought disorders. The blood samples were drawn from the ante-cubital vein in the morning. Genomic DNA used for the polymerase chain reaction (PCR) was extracted from the whole blood sample. The sequence containing the Pst I polymorphic site in the boundary between intron 1 and exon 2 of the CCK-A receptor gene was amplified by a PCR-based process with a pair of primers, 5Ј-CTGTTCACTTGAG GAGCTTTG-3Ј (sense strand) and 5Ј-TTAGA AACTGACCTCCAACATGG-3Ј (antisense strand). Pst I digestion of the PCR products gave two individual alleles, A1 and A2. A1 allele was the undigested fragment and A2 allele was the digested one with two variant bands at 264 bp and 480 bp. Allelic frequencies were 0.25 (A1) and 0.75 (A2) in unrelated schizophrenic patients, and 0.2 (A1) and 0.8 (A2) in unrelated controls. The distribution of genotypic frequencies was in Hardy-Weinberg equilibrium in both unrelated patients and unrelated control subjects. The chi-square ( 2 ) test did not show a significant difference in either allelic or genotypic frequencies between schizophrenic patients and control subjects.
These patients were sub-grouped based on each symptom they had or on whether or not they had a family history of mental illness, so that a genetic association with a psychiatric symptom or with family history was then tested. In the present study, we did not find a significant difference in either allelic or genotypic frequencies between patients with auditory hallucinations and those without auditory hallucinations, but a significant difference in allelic frequency was found between patients with the HDS and those without the HDS ( 2 = 4.403, d.f. = 1, P = 0.036); the odds ratio (OR) for the allelic association was 2.14 (95% CI 1.043-4.414) with an attributable fraction (AF) of 0.188. In addition, a significant difference in allelic frequency was shown between schizophrenic patients with the HDS and control subjects ( 2 = 4.89, d.f. = 1, P = 0.027), with an OR of 2.17 (95% CI 1.08-4.45) and an AF of 0.2, but no significant difference was found between patients without the HDS and control subjects. As shown in Table 1 , patients with the HDS had an excess of A1-A1 and A1-A2 genotypes as compared with those without the HDS ( 2 = 6.552, d.f. = 1, P = 0.01), and the frequency of A1-A1 and A1-A2 genotypes was also significantly higher in patients with family history than in those wihtout family history ( 2 = 4.468, d.f. = 1, P = 0.035). However, the present results did not show any association of the CCK-A receptor gene with other psychotic symptoms.
In this study, unlike the previous findings, 11 we failed to replicate the association of the CCK-A receptor gene with auditory hallucinations in a Chinese population. This suggests at least two possibilities, although a false positive result cannot be ruled out, that the genes for schizophrenia may not specifically determine a single psychotic symptom on the one hand; and on the other hand, ethnic cultures may influence the clinical expression of a schizophrenic illness. Since both the HDS and auditory hallucinations are the positive symptoms commonly occurring in schizophrenia, it could be hypothesized that the CCK-A receptor gene may be associated with the positive symptoms of schizophrenia. In a recent study conducted with a large sample size, we also found that the CCK-A receptor gene was significantly associated with the HDS in a Caucasian population (unpublished data). The A1 frequency was 0.176 in schizophrenic patients with the HDS and 0.087 in those without the HDS ( 
Interaction of two genes possibly involved in the regulation of the amyloid precursor protein (APP) processing
SIR -An intronic polymorphism of the gene encoding the transmembrane protein presenilin 1 (PS1) was found to be associated with increased risk for sporadic AD (ie over-representation of allele 1 in AD), 1 however, this observation has been challenged by subsequent studies. These inconsistent findings might result from interactions of PS1 with other susceptibility genes and their products. Recently, Xia et al 2 identified PS1 to be crucial for the catalytic activity of the ␥-secretase, which is one of the two yet unidentified proteases (␤-and ␥-secretase) responsible for cleavage of the amyloid precursor protein (APP) into amyloidogenic components (␤A4).
Cathepsin D (catD), an acid protease active in intracellular protein breakdown, has in vitro ␤-and ␥-secretase-like properties and has also been implicated in the pathogenesis of AD. An exonic polymorphism of the catD gene (allele T) was recently found to be a major risk factor for the development of sporadic AD.
3 Wolfe et al 4 proposed that ␥-secretase is an aspartyl protease with properties similar to those of cathepsin D. Thus, both genetic and biochemical data suggest an involvement of PS1 and catD in the cleavage and further processing of APP. Given this evidence, we hypothesised that genetic interactions between PS1 and catD would modify the risk for the development of sporadic AD and might be responsible for the conflicting reports on the association of the PS1 genotype with AD.
We investigated a sample of 217 patients with sporadic AD (mean age 72.6 ± 9.7 years, 62.2% female) and of 434 non-demented control subjects (mean age 68.2 ± 10.6 years, 56.0% female) recruited at two centres 
